To Identify Potential New Urine Markers for the Screening of Prostate Cancer

Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 11, 2019

Keywords

ClinConnect Summary

This clinical trial is studying new ways to detect prostate cancer using urine samples. Prostate cancer is a serious health issue for men, and the current method of using a blood test called PSA (prostate-specific antigen) isn’t always accurate. Many men with high PSA levels do not actually have prostate cancer, which can lead to unnecessary procedures like biopsies. Researchers believe that measuring certain substances in urine, especially a compound called spermine, might provide a more reliable and easier way to diagnose prostate cancer.

To participate in this study, men aged 18 and older who have a PSA level above 4 ng/ml and are scheduled for a prostate biopsy may be eligible. However, those who have had a recent urinary infection, certain medical procedures, or specific medications in the past six months are not able to join. Participants will provide urine samples, which will be analyzed to see if these new markers can help in diagnosing prostate cancer more accurately. This study aims to improve how prostate cancer is diagnosed and managed, potentially leading to better outcomes for patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult male patients with age \> 18 years old
• • 2. Subject has elevated serum PSA level above 4ng/ml
• • 3. Clinical planned for prostatic biopsy.
• Exclusion Criteria:
• • 1. Patient with recent urinary tract infection within 6 weeks prior to PSA testing and urine collection.
• • 2. Patient with recent urethral instrumentation, such as Foley catheter insertion, cystoscopy etc, within 6 weeks prior to PSA testing and urine collection.
• • 3. Patient with consumption of 5 alpha reductase inhibitors in past 6 months.
• • 4. Patient did not receive any surgery for prostatic pathology
• • 5. Patient refused or unable to provide consent for the study